Sfoglia per AUTORE
SALUTARI V
Collezione AO Ordine Mauriziano

  

Items : 12

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5.
2024
AO Ordine Mauriziano

Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G;

Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30.
2024
AO Ordine Mauriziano

Tuninetti V; Virano E; Salutari V; Ricotti A; Pisano C; Ducceschi M; Turitto G; Scandurra G; Petrella MC; Forestieri V; Rizzetto M; Mammoliti S; Artioli G; Cioffi R; Borsotti L; Bellero M; Rognone C; Carbone V; Ferrandina G; Mantiero M; Azzolina C; Geninatti E; Pignata S; Valabrega G;

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3.
2024
AO Ordine Mauriziano

Pignata S; Califano D; Lorusso D; Arenare L; Bartoletti M; De Giorgi U; Andreetta C; Pisano C; Scambia G; Lombardi D; Farolfi A; Cinieri S; Passarelli A; Salutari V; De Angelis C; Mignogna C; Priolo D; Capoluongo ED; Tamberi S; Scaglione GL; Arcangeli V; De Cecio R; Scognamiglio G; Greco F; Spina A; Turinetto M; Russo D; Carbone V; Casartelli C; et alii...

Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial. in The International journal of biological markers / Int J Biol Markers. 2024 Dec;39(4):328-337. doi: 10.1177/03936155241296164. Epub 2024 Nov 8.
2024
AO Ordine Mauriziano

Indraccolo S; Signoriello S; Piga I; Esposito G; Ferrarini F; Boscolo Bragadin A; Salutari V; Pisano C; Califano D; Bignotti E; Tognon G; Simeon V; Artioli G; Ferrero A; Cinieri S; Bologna A; Chiodini P; Scognamiglio G; Bottoni C; Spina A; Russo D; Arenare L; Perrone F; Pignata S;

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. in Gynecologic oncology / Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.
2023
AO Ordine Mauriziano

Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S;

2023
AO Ordine Mauriziano

Colombo N; Gadducci A; Landoni F; Lorusso D; Sabbatini R; Artioli G; Berardi R; Ceccherini R; Cecere SC; Cormio G; De Angelis C; Legge F; Lissoni A; Mammoliti S; Mangili G; Naglieri E; Petrella MC; Ricciardi GRR; Ronzino G; Salutari V; Sambataro D; Savarese A; Scandurra G; Tasca G; Tomao F; Valabrega G; Zavallone L; Pignata S;

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G; Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; et alii...

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. in Cancer treatment reviews / Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24.
2022
AO Ordine Mauriziano

Musacchio L; Valsecchi AA; Salutari V; Valabrega G; Camarda F; Tuninetti V; Giannone G; Bartoletti M; Marchetti C; Pignata S; Fagotti A; Scambia G; Di Maio M; Lorusso D;

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). in British journal of cancer / Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.
2022
AO Ordine Mauriziano

Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S; et alii...

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. in Frontiers in oncology / Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022.
2022
AO Ordine Mauriziano

Giannone G; Castaldo D; Tuninetti V; Scotto G; Turinetto M; Valsecchi AA; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30.
2021
AO Ordine Mauriziano

Gallo C; Schettino C; Gargiulo P; Greggi S; Distefano M; Bogani G; Nardin M; Lapresa M; Cecere SC; Salutari V; Lorusso D; Katsaros D; Lissoni AA; Scollo P; De Giorgi U; Cinieri S; De Censi A; Breda E; Ferrero A; Lauria R; Gadducci A; Tognon G; Artioli G; Frezzini S; Colombo N; Pisano C; Scambia G; Raspagliesi F; Arenare L; et alii...